Sign up Australia
Proactive Investors - Run By Investors For Investors

HC Wainwright repeats 'buy' on Cynata as ongoing trial is cleared by data safety monitoring board

Analyst Raghuram Selvaraju repeated a 'buy' stance and targets A$1.50 for the shares
HC Wainwright repeats 'buy' on Cynata as ongoing trial is cleared by data safety monitoring board
Aussie-listed Cynata is a stem cell group

Broker HC Wainwright is bullish on stem cell group Cynata Therapeutics Ltd (ASX:CYP) following encouraging early findings from clinical trials of its CYP-001 treatment for steroid-resistant graft-versus-host disease.

The data safety monitoring board has now recommended that the group's clinical trial progress to a second Cohort of patients.

READ: Cynata Therapeutics wins U.S. patent for stem cell technology

Analyst Raghuram Selvaraju repeated a 'buy' stance and targets A$1.50 for the shares, which is more than double where they are now - at A$0.64 (up 8.47%).

"All eight participants in Cohort A have demonstrated at least a partial response, which is defined as an improvement in the severity of their graft-vs. host disease (GvHD) by at least one grade vs. baseline. In addition, thus far no treatment-related serious adverse events (SAEs) or safety concerns have been observed. Patient enrollment for Cohort B is now open at seven trial sites in the UK and Australia," said the analyst.

In Cohort B, it is planned that a further eight participants would receive two CYP-001 infusions each at a higher dose level - up to a maximum of 200M cells per infusion, the broker added.

View full CYP profile View Profile

Cynata Therapeutics Ltd Timeline

Related Articles

1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use